Scientists develop a new cancer vaccine: the cure rate of mice is 97%
On April 16th, according to British media reports, a cancer vaccine that has been tested on mice to prove hematoma efficiency as high as 97% will be tested in humans later this year for the treatment of low-grade lymphoma. . Vaccinated patients will not need any chemotherapy, and the side effects may be just fever and pain at the injection site. Researchers predict that if the trial is successful, it will be ready for use in less than 1-2 years. This vaccine does not work by bringing about sustained immunity, but activates the immune system against tumors. This is effective for low-grade lymphomas. Unlike other cancers, such as colon cancer, lymphoma affects only certain white blood cells, often found by the immune system, and usually responds to treatment. About 1.7 million people in the United States suffer from cancer every year. The first author of the paper, Dr. Ronald Levy of Stanford University, said: "We are facing huge problems in conquering cancer, and we will never be satisfied until we find a solution for everyone." The vaccine test will pass two rounds of research. There were 35 patients who participated in the test. Two rounds of vaccination were given for six weeks, during which each participant received a low dose of radiation. Other details such as the interval between vaccinations are unclear. Similar therapeutic approaches to the immune system have been approved for the treatment of various leukemias and lymphomas. The method is to separate the immune cells from the patient, and then genetically engineer and inject into the body to attack the tumor cells. However, this treatment, called CAR-T, costs about $500,000 per patient and can cause symptoms such as fever, confusion, organ failure, and immune system disorders. Cancer researcher Dr. Michel Hermiston of the University of California said: "This is not a worthless approach." She said the study should be used to determine whether it is possible to artificially control the tumor to better respond to the immune system. . Dr. Hermiston also said: "Can we make the immune system easier to find tumors? We are still at the tip of the iceberg." The researchers transplanted two identical tumors to different parts of the mouse body, one of which was activated by injection. T cell vaccine. These cells stimulate an immune response against substances such as viruses that invade the animal's body. The extent of the response is measured by the effect of the vaccine on untreated tumors. The test results show that the vaccine can treat a variety of cancers and prevent disease. These research results have been published in the journal Science Translational Medicine. Tetanus Vaccine,Hepatitis B Vaccine For Adults,Tetanus Booster,Td Vaccine FOSHAN PHARMA CO., LTD. , https://www.foshanpharma.com